DEXONE 4
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DEXONE 4 (DEXONE 4).
Dexamethasone is a long-acting glucocorticoid receptor agonist, binding to glucocorticoid response elements to modulate gene transcription, resulting in anti-inflammatory, immunosuppressive, anti-allergic, and anti-shock effects.
| Metabolism | Primarily hepatic via cytochrome P450 3A4 (CYP3A4) to inactive metabolites. |
| Excretion | Renal excretion of metabolites (<5% unchanged drug); minor biliary/fecal elimination (<1%) |
| Half-life | Terminal elimination half-life: 2-3 hours (oral); clinical effects persist longer due to glucocorticoid receptor-mediated genomic actions |
| Protein binding | 77% bound primarily to corticosteroid-binding globulin (CBG) and albumin |
| Volume of Distribution | 0.6-1.0 L/kg; indicates extensive distribution into total body water, with higher volume in obese patients |
| Bioavailability | Oral: 80-90%; Intramuscular: 80-100% |
| Onset of Action | Oral: 1-2 hours; Intravenous: immediate (minutes); Intramuscular: 1-2 hours |
| Duration of Action | Duration of metabolic effects: 24-36 hours (based on hypothalamic-pituitary-adrenal axis suppression); clinical duration varies with dose and condition |
| Molecular Weight | 392.46 |
Oral: 0.75–9 mg/day divided every 6–12 hours; IV/IM: 0.5–9 mg/day divided every 6–12 hours.
| Dosage form | TABLET |
| Renal impairment | No specific GFR-based adjustment required; use with caution in severe renal impairment due to fluid retention. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%. |
| Pediatric use | 0.02–0.3 mg/kg/day or 0.6–9 mg/m²/day in divided doses every 6–12 hours. |
| Geriatric use | Initiate at lowest effective dose; monitor for osteoporosis, hyperglycemia, and fluid retention; adjust dose based on response and tolerance. |
| 1st trimester | Dexamethasone crosses the placenta and is classified as a corticosteroid with potential teratogenic effects in first trimester. Use only if clearly needed; may increase risk of cleft palate. |
| 2nd trimester | Use during second trimester may increase risk of intrauterine growth restriction and adrenal suppression in the fetus. |
| 3rd trimester | Use in third trimester can cause fetal adrenal suppression and hyperglycemia in the mother and neonate. Monitor for signs of infection and glucose levels. |
Clinical note
Comprehensive clinical and safety monograph for DEXONE 4 (DEXONE 4).
| Placental transfer | Dexamethasone readily crosses the placenta with about 25% of maternal plasma concentration reaching the fetal circulation. It is metabolized in the placenta but active drug reaches the fetus. |
| Breastfeeding | Dexamethasone is excreted into breast milk in low concentrations. However, due to potential for immunosuppression, growth suppression, and interference with endogenous corticosteroid production in the infant, caution is advised. Use lowest effective dose for shortest duration if necessary. |
■ FDA Black Box Warning
Corticosteroids may cause dose-dependent suppression of the hypothalamic-pituitary-adrenal (HPA) axis, leading to adrenal insufficiency or crisis upon withdrawal or stress. Avoid abrupt discontinuation.
| Serious Effects |
Systemic fungal infections (unless used for life-threatening shock)Hypersensitivity to dexamethasone or any componentAdministration of live or live-attenuated vaccines during therapy
| Precautions | Increased risk of infections; masking of infection signs; gastrointestinal perforation; osteoporosis; HPA axis suppression; growth suppression in children; psychiatric disturbances; ocular effects (glaucoma, cataracts); hypertension; congestive heart failure; thromboembolism; anaphylactoid reactions. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as CYP3A4 inhibitors increase dexamethasone exposure. High-sodium foods may exacerbate fluid retention. Limit caffeine intake due to increased risk of hypokalemia. Maintain adequate calcium and vitamin D intake to prevent osteoporosis. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Corticosteroids are associated with a small increased risk of orofacial clefts (absolute risk increase ~0.1-0.2%). Second/third trimester: Chronic use may cause fetal adrenal suppression, growth restriction, and oligohydramnios. Risk is dose- and duration-dependent. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of infection. For prolonged therapy, fetal growth ultrasound and amniotic fluid volume assessment are recommended. Monitor newborn for signs of adrenal suppression if used near term. |
| Fertility Effects | No direct evidence of impaired fertility in humans. Corticosteroids may affect ovulation and spermatogenesis at high doses, but clinically significant effects are unlikely. |
| Clinical Pearls | DEXONE 4 (dexamethasone 4 mg) is a potent glucocorticoid with minimal mineralocorticoid activity. Use for cerebral edema, severe allergies, and COVID-19-associated hypoxia. Taper to avoid adrenal insufficiency. Monitor for hyperglycemia, especially in diabetics. Contraindicated in systemic fungal infections and live vaccine administration. |
| Patient Advice | Take with food or milk to reduce gastric irritation. · Do not stop abruptly; follow tapering schedule. · Report any signs of infection (fever, sore throat) or unusual bruising. · Monitor blood glucose if diabetic. · Avoid live vaccines during treatment. |